FDA clearance of an IND is a critical regulatory milestone for biotech companies, often leading to increased investor confidence and potential stock price appreciation. As SC262 directly pertains to Sana Biotechnology's core business and future revenue potential, this news is highly relevant and important for investors. The positive impact on the stock price is likely, although the degree of movement will depend on broader market conditions and investor sentiment towards the biotech sector.